We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

117 hedge funds and large institutions have $164M invested in Rigel Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 35 increasing their positions, 38 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,976% more call options, than puts

Call options by funds: $1.04M | Put options by funds: $50K

42% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 12

4% more funds holding

Funds holding: 112 → 117 (+5)

0.61% less ownership

Funds ownership: 6.94% → 6.33% (-0.61%)

8% less repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 38

7% less capital invested

Capital invested by funds: $176M → $164M (-$11.8M)

Holders
117
Holders Change
+5
Holders Change %
+4.46%
% of All Funds
1.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
35
Reduced
38
Closed
12
Calls
$1.04M
Puts
$50K
Net Calls
+$988K
Net Calls Change
-$324K

Top Buyers

1
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
+$1.83M
2
Millennium Management
Millennium Management
New York
+$1.48M
3
SCM
Stonepine Capital Management
Oregon
+$1.4M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.14M
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$1.12M

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$19.5M
2
AC
Armistice Capital
New York
-$2.34M
3
SFM
Sphera Funds Management
Israel
-$1.78M
4
BlackRock
BlackRock
New York
-$538K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$532K
Name Holding Trade Value Shares
Change 		Change in
Stake
Los Angeles Capital Management
26
Los Angeles Capital Management
California
$893K +$268K +19,871 +49%
Squarepoint
27
Squarepoint
New York
$886K +$370K +27,453 +85%
BCM
28
Bridgeway Capital Management
Texas
$881K -$101K -7,500 -11%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$776K -$56.5K -4,193 -7%
Marshall Wace
30
Marshall Wace
United Kingdom
$649K +$591K +43,856 New
Citadel Advisors
31
Citadel Advisors
Florida
$642K +$551K +40,877 +1,637%
ZIM
32
Zacks Investment Management
Illinois
$628K +$164K +12,193 +40%
Goldman Sachs
33
Goldman Sachs
New York
$606K -$138K -10,226 -20%
AllianceBernstein
34
AllianceBernstein
Tennessee
$466K – – –
XT
35
XTX Topco
Cayman Islands
$466K +$349K +25,889 +465%
EFMC
36
Empire Financial Management Company
New York
$451K +$150K +11,150 +58%
BNP Paribas Financial Markets
37
BNP Paribas Financial Markets
France
$374K +$66.3K +4,923 +24%
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$352K +$10.9K +809 +4%
Fidelity Investments
39
Fidelity Investments
Massachusetts
$306K +$2.49K +185 +0.9%
NSEDCP
40
NJ State Employees Deferred Compensation Plan
New Jersey
$296K – – –
UBS Group
41
UBS Group
Switzerland
$265K +$37.5K +2,780 +18%
SO
42
STRS Ohio
Ohio
$261K – – –
Two Sigma Investments
43
Two Sigma Investments
New York
$226K +$67.2K +4,986 +48%
Barclays
44
Barclays
United Kingdom
$223K -$129K -9,593 -39%
Susquehanna International Group
45
Susquehanna International Group
Pennsylvania
$198K -$224K -16,601 -55%
Man Group
46
Man Group
United Kingdom
$179K +$163K +12,100 New
Russell Investments Group
47
Russell Investments Group
United Kingdom
$174K -$37.9K -2,810 -19%
CWM
48
Connecticut Wealth Management
Connecticut
$170K – – –
T. Rowe Price Associates
49
T. Rowe Price Associates
Maryland
$168K +$12.3K +912 +9%
Bank of America
50
Bank of America
North Carolina
$166K -$78.7K -5,842 -34%
1
2
3 4 5

RIGL Hedge Fund Activity: Q1 2024 in Review

117 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2024, worth a combined $164M — down 6.7% from $176M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new RIGL positions and 12 closed out — a net gain of 5 holders — while 35 added to existing stakes and 38 trimmed.

The largest buyer was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, opening a new position worth an estimated $1.83M. The largest seller was Morgan Stanley, cutting an estimated $19.5M.

  • 117 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2024, up from 112 in Q4 2023.
  • Funds reported $164M of Rigel Pharmaceuticals stock for Q1 2024, down 6.7% quarter-over-quarter.
  • 17 funds opened new Rigel Pharmaceuticals positions in Q1 2024 and 12 closed out, a net change of +5 holders.
  • The largest Rigel Pharmaceuticals buyer in Q1 2024 was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, an estimated $1.83M added.
  • The largest Rigel Pharmaceuticals seller in Q1 2024 was Morgan Stanley, an estimated $19.5M sold.

Based on aggregated 13F filings for Q1 2024.